Eclipsebio logo
Contact Us

Analysis of the combined effect of rs699 and rs5051 on angiotensinogen expression and hypertension

  • Published April 8, 2023
  • by Eclipsebio

Share

Intro text lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Related articles

eCOMPASS provides lab-in-the-loop optimization of RNA therapeutics

eBlogs

04
10
26

eCOMPASS: Onboarding an RNA therapeutic project with Eclipsebio 

eCOMPASS guides drug developers to the optimal candidate with its lap-in-the-loop platform.

read more
Tailored designs for RNA therapeutics

eBlogs

03
06
26

Manufacturing-informed design in therapeutic development  

Successful lab-in-the-loop approaches optimize RNA therapeutic design to be easily manufactured and produced.

read more

Grants

02
12
26

2026 mRNA Innovators Award Call for Applications

The mRNA Innovators Award offers matching funds to design and validate a therapeutic of interest using Eclipsebio's design models and characterization methods.

read more
Eclipsebio's closed-loop RNA drug discovery platform

eBlogs

02
07
26

The power of pairing RNA design and analytics 

Discover how closed-loop RNA development pairs design and sequencing to accelerate better therapeutics.

read more